PLIANT THERAPEUTICS, INC.

PLRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-149.3M $-210.3M $-161.3M $-123.3M $-97.3M $-41.5M $-631.0K
Depreciation & Amortization
Depreciation $1.7M $2.1M $1.8M $1.8M $1.5M $1.3M $1.1M
Amortization
Stock-Based Compensation $26.2M $37.6M $44.5M $22.6M $10.4M $3.9M $1.8M
Net Cash from Operating Activities $-128.3M $-155.5M $-116.4M $-94.6M $-75.4M $-37.3M $-2.8M
Investing Activities
Capital Expenditures $374.0K $3.8M $921.0K $1.8M $2.0M $1.5M $964.0K
Business Acquisitions
Net Cash from Investing Activities $134.3M $140.3M $-127.0M $-150.2M $73.7M $-210.9M $-17.9M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $-31.7M $23.1M $274.4M $226.9M $2.5M $213.2M $45.5M
Net Change in Cash $-25.7M $8.0M $31.0M $-18.0M $783.0K $-34.9M $24.9M
Free Cash Flow $-128.7M $-159.4M $-117.3M $-96.4M $-77.4M $-38.8M $-3.7M